Biological and Pharmaceutical Bulletin
Online ISSN : 1347-5215
Print ISSN : 0918-6158
ISSN-L : 0918-6158
Current Topics
Abnormalities in Itch Sensation and Skin Barrier Function in Atopic NC/Tnd Mice
Yosuke AmagaiHiroshi MatsudaAkane Tanaka
著者情報
ジャーナル フリー HTML

2013 年 36 巻 8 号 p. 1248-1252

詳細
Abstract

Atopic dermatitis (AD) is a chronic inflammatory skin disease characterized by dryness and itchy skin. Genetic factors as well as other factors, including abnormality in skin barrier function, hypersensitivity of itch sensory nerves, and dysfunction of the immune system, strongly affect the onset and exacerbation of AD. Recently, it has become clear that itch sensation is closely related to pain sensation. By using NC/Tnd mice, a unique spontaneous animal model for human AD, we found abnormalities in sensitivity against external stimuli as compared to two standard strains, BALB/c and B6 mice. Particularly, in conventional NC/Tnd mice with AD, stimulation against transient receptor potential (TRP) V1 reduced the scratching behavior, suggesting the possibility of a TRPV1 modulator in the treatment of atopic itch. The review outlines observations regarding itch sensation and skin barrier function in NC/Tnd mice by using a novel itch quantification system for the laboratory animals, which may bring great progress in the future study of itch.

1. INTRODUCTION

Atopic dermatitis (AD) is a chronic and relapsing skin disorder with inflammatory or pruritic skin symptoms, and is one of the most common skin diseases.1) It often occurs in families with other atopic diseases such as bronchial asthma, allergic rhinitis, and conjunctivitis.1) The etiology of AD is multifactorial; the relations of genetic, environmental, immunological, and psychological factors, as well as physical ones such as skin barrier to the disease, have been reported.25) Among these, loss-of-function mutations within the profilaggrin gene (FLG gene) is one genetic factor that correlates to the exacerbation of AD, and has been found in approximately 20% of AD patients.4) Because filaggrin, the cleaved form of profilaggrin, is essential for the regulation of epidermal homeostasis, it indicates the importance of factors that impact skin barrier function, including those which are not oriented from genetic backgrounds.6) In fact, for example, abnormal microbial colonization such as Staphylococcus aureus is reported to accelerate the exacerbation of the symptoms.7)

The skin barrier can be mechanically damaged by scratching behavior, derived from the itch sensation, which is one of the most problematic symptoms of AD.810) The control of itch sensation is difficult because the itch sensation evokes the scratching behaviors, which worsen the disease by triggering the release of pro-inflammatory cytokines, including tumor necrosis factor α (TNF-α) and interleukin-2 (IL-2), from keratinocytes, as well as itch sensation-enhancing neuropeptides such as substance P or calcitonin gene related peptide (CGRP) from C fiber.11,12) These factors further stimulate the vascular endothelial cells or mast cells to produce chemical mediators such as histamine, consequently producing a “vicious circle” of disease exacerbation. Recently, while the mechanisms of itch sensation have become clear, controversy remains regarding how to distinguish between itch and pain sensation. In this review, we introduce discoveries regarding the pain/itch sensation, as well as skin barrier function, which severely affect the itch sensation, using NC/Tnd mice, a useful animal model for human AD (Fig. 1).

Fig. 1. Specific-Pathogen Free (SPF) (Left) and Conventional (Right) NC/Tnd Mice

AD-like skin lesions spontaneously develop in conventional NC/Tnd mice around 7 weeks of age, but not in SPF NC/Tnd mice.

2. CONTROVERSIES REGARDING ITCH/PAIN SENSATION

There have been two theories regarding the itch/pain sensation. One is the concept that itch and pain are perceived by distinct nerves that are specialized in processing each sensation. This theory is supported by several reports, such as the discovery of nerve fibers that specifically transduce the itch sensation. Namer et al.13) identified distinct populations of C-fibers that react to the corresponding itch sensations in human. In addition, Sun et al.14) demonstrated that gastrin releasing peptide receptor-positive neuronal cells in the spinal cord were specific for the itch sensation in mice. Another theory describes the same afferent neurons being capable of triggering both itch and pain sensations, depending on the pattern or intensity of the stimulation. It is supported by the findings that a voltage-dependent cation channel, transient receptor potential (TRP) V1 and TRPA1 are responsible for evoking itch sensation, though these receptors had previously been recognized as pain-sensing receptors.15,16) Mechanisms of itch sensation are still complicated; however, recent findings, including ours, indicate that some neuronal signals may exert an influence on both itch and pain sensation. The next chapter describes what we have found regarding the itch sensation by using NC/Tnd mice.

3. OBSERVATIONS REGARDING ITCH SENSATION IN THE MOUSE MODEL OF AD

Recently, we found that the neural response to capsaicin, which is one of the major stimuli that evokes pain, is much lower in NC/Tnd mice than in other strains (article in preparation, Table 1). Interestingly, scratching behavior caused by histamine, which shares the TRPV1 signaling with capsaicin,15,16) was not different between NC/Tnd mice and two other standard strains (Table 2). On the other hand, responses to other pruritogens, including serotonin (phospholipase Cβ3-dependent),17) chloroquine and SLIGRL-NH2 (TRPA1-dependent),18) were significantly lower in NC/Tnd mice (Table 2). These results indicate an alteration in the skin sensitivity of NC/Tnd mice, probably resulting in an increase of itch sensation via TRPV1 receptors. It also raised the possibility that disruption of the itch/pain sensation balance may drive the itch sensation in AD. A TRPV1 antagonist has been reported to have potential as a therapeutic agent for itching in both pruritogen-induced allergic dermatitis models and spontaneous NC/Nga mice.19,20) On the other hand, a TRPV1 agonist, capsaicin, has been reported to exert a moderate suppressive effect on histamine-, substance P-, and proteinase-activated receptor-2 (PAR-2) agonist-induced itch responses.21) By using conventional NC/Tnd mice, we have already confirmed that serious scratching behavior was decreased after the application of capsaicin onto the affected skin (data in preparation). The different information indicates that modulating the itch/pain balance through the TRP channel family may be a novel strategy for controlling itch in AD (Fig. 2).

Fig. 2. Hypotheses Regarding the Onset of Atopic Dermatitis

Low activity of a pain-reactive neuron may be associated with the dysfunction of the itch/pain sensation balance, leading to the enhancement of itch sensation and scratching behavior. These alterations, as well as skin barrier dysfunction caused by other factors (e.g., genetic background), may accelerate the impairment of the skin barrier, which brings about the exacerbation of dermatitis.

Table 1. Ca2+ Influx Level of Dorsal Root Ganglion (DRG) Neuronal Cells after Capsaicin Stimulation
StrainCa2+ influx
BALB/c+++
C57BL/6+++
NC/Tnd (SPF)+

The response level of DRG neuronal cells to capsaicin was indicated. Compared to BALB/c and C57BL/6 mice, NC/Tnd mice under the SPF condition showed lower response to capsaicin. −, none; +, weak; ++, moderate; +++, strong.

Table 2. Scratching Behavior of NC/Tnd Mice Caused by Several Pruritogens
StrainPruritogen
ControlHistamineSerotoninChroloquineSLIGRL-NH2
BALB/c+++++++++
C57BL/6+++++++++
NC/Tnd (SPF)+++++

 Scratching frequency level of NC/Tnd mice after topical application of 4 different pruritogens on dorsal skin was indicated. −, <20 times; +, 20–50 times; ++, 51–100 times; +++ >100 times of scratching behavior/1 h.

4. OBSERVATIONS OF SKIN BARRIER FUNCTION IN THE MOUSE MODEL OF ATOPIC DERMATITIS

As mentioned above, scratching behavior damages skin barrier function. Cutaneous abnormalities such as dry skin may initiate the itch sensation, thus there is a close relationship between itch and skin barrier function. We have already revealed that the ceramide content in skin is decreased in conventional NC/Tnd mice with AD, which impairs the water retention of the skin.22) In NC/Tnd mice, the generation and supplementation of ceramide in the stratum corneum during development of AD is insufficient due to the low activity of sphingomyelinase.22) However, factors which trigger the itch sensation after barrier disruption of the skin has been unclear. Recently, we found that ingredients taken from drinking water altered the clinical severity of dermatitis in the mouse model.23) In the study, soft ground water from Jeju Island, which contains little magnesium and calcium, was superior to hard water for the prevention of scratching behavior in NC/Tnd mice with AD (Fig. 3), indicating that the intake of mineral ions exhibits certain effects on modulating allergic features.22)

Fig. 3. Changes in Scratching Frequency after Supplementation of Various Kinds of Bottled Water

The graph indicates the number of scratching behaviors of NC/Tnd mice that had been supplied tap water or very soft Jeju ground water for the indicated period. Each value represents means±S.E. of 10 mice in each group. * p<0.05, when compared with the control group supplied tap water for 8 weeks.

5. SCLABA-REAL®, A NOVEL SCRATCH ANALYZING SYSTEM

Itch is one of the most serious sensations for the exacerbation of AD. For the alleviation of AD symptoms, controlling both itching and scratching is the most important issue. Measurement of scratching behavior of laboratory mice gives valuable information for us to develop new treatments for atopic itch; however, quantitative analysis of scratching behavior of mice was quite difficult. SCLABA-Real® is a novel system for the real-time quantification of scratching behavior in laboratory mice without performing any kinds of stressful operations on the mouse24,25) (Fig. 4). Conventionally, experimenters had to count the number of the scratching incidents, which required a lot of tasks and time. Instead, SCLABA-Real® enabled us to analyze the scratching behavior of four mice, by simultaneously recording the motion of each mouse with a high-speed digital camera from the top of an exclusive cage placed on near-infrared light. SCLABA-Real® software accurately detects the algorithm that is specific for scratching behavior in mice and records data in real-time. Basically, it captures animal behavior at the rate of 240 frames per second using a high-speed camera containing an image processing system, making it possible to quantify the number and duration of scratching behavior automatically by time-course analysis of “frame-to-frame difference.”24,25) This analysis method is advantageous in the successive measurement of itch/scratch because it does not cause stress on mice. In addition, it does not require much additional time for the analysis, as frame-to-frame pictures are instantly sent to the hard disk of a computer through the video server and LAN, and analyzed at the same time. Moreover, the usage of invisible near-infrared light and a timer enables us to capture the behavior in the darkness automatically. Therefore, this system can detect alterations of scratching behavior under normal conditions.

Fig. 4. A Novel Scratch Analyzing System, SCLABA-Real®

The high-speed camera containing an image processing system and the recording platform with a built-in near-infrared light panel for real-time quantification of scratching behavior of mice (A). Real time record and analysis window (B).

6. REMARKS

Compared to the artificially induced model, the spontaneous AD model provides valuable information regarding the pathogenesis, sensitivity and barrier function in the skin, and aids in the selection of effective new drugs and supplements. Because AD is a multifactorial disease, the utilization of proper experimental models is necessary for the discovery of therapeutic targets. Recent findings, including in vivo data using NC/Tnd mice, indicate the complexity of itch sensation, though at the same time the model may provide valuable information for the drug discovery for AD. By using NC/Tnd mice, we found that TRPV1 may be an appropriate target to control unbearable itch sensation in AD. Besides evaluating scratching frequency, it also provides useful information for the screening of compounds because itch is one of the outcomes resulting from the mixture of multiple pathogenic alterations. Thus, applications of an accurate scratch analyzer on animal models of AD will provide a useful platform for further research.

REFERENCES
  • 1)  Johansson SGO, Hourihane JO, Bousquet J, Bruijnzeel-Koomen C, Dreborg S, Haahtela T, Kowalski ML, Mygind N, Ring J, van Cauwenberge P, van Hage-Hamsten M, Wüthrich B. Guidelines for treatment of atopic eczema (atopic dermatitis) Part I. Allergy, 56, 813–824 (2001).
  • 2)  Williams HC. What is atopic dermatitis and how should it be defined in epidemiological studies? Cambridge University Press, pp. 3–24 (2000).
  • 3)  Schmid-Ott G, Jaeger B, Meyer S, Stephan E, Kapp A, Werfel T. Different expression of cytokine and membrane molecules by circulating lymphocytes on acute mental stress in patients with atopic dermatitis in comparison with healthy controls. J. Allergy Clin. Immunol., 108, 455–462 (2001).
  • 4)  Palmer CN, Irvine AD, Terron-Kwiatkowski A, Zhao Y, Liao H, Lee SP, Goudie DR, Sandilands A, Campbell LE, Smith FJ, O’Regan GM, Watson RM, Cecil JE, Bale SJ, Compton JG, DiGiovanna JJ, Fleckman P, Lewis-Jones S, Arseculeratne G, Sergeant A, Munro CS, El Houate B, McElreavey K, Halkjaer LB, Bisgaard H, Mukhopadhyay S, McLean WH. Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis. Nat. Genet., 38, 441–446 (2006).
  • 5)  Cork MJ, Danby SG, Vasilopoulos Y, Hadgraft J, Lane ME, Moustafa M, Guy RH, Macgowan AL, Tazi-Ahnini R, Ward SJ. Epidermal barrier dysfunction in atopic dermatitis. J. Invest. Dermatol., 129, 1892–1908 (2009).
  • 6)  O’Regan GM, Sandilands A, McLean WH, Irvine AD. Filaggrin in atopic dermatitis. J. Allergy Clin. Immunol., 122, 689–693 (2008).
  • 7)  Zollner TM, Wichelhaus TA, Hartung A, Von Mallinckrodt C, Wagner TO, Brade V, Kaufmann R. Colonization with superantigen-producing Staphylococcus aureus is associated with increased severity of atopic dermatitis. Clin. Exp. Allergy, 30, 994–1000 (2000).
  • 8)  Beltrani VS. Suggestions regarding a more appropriate understanding of atopic dermatitis. Curr. Opin. Allergy Clin. Immunol., 5, 413–418 (2005).
  • 9)  Proksch E, Fölster-Holst R, Jensen JM. Skin barrier function, epidermal proliferation and differentiation in eczema. J. Dermatol. Sci., 43, 159–169 (2006).
  • 10)  Boguniewicz M. Atopic dermatitis: beyond the itch that rashes. Immunol. Allergy Clin. North Am., 25, 333–351, vii (2005).
  • 11)  Sun YG, Chen ZF. A gastrin-releasing peptide receptor mediates the itch sensation in the spinal cord. Nature, 448, 700–703 (2007).
  • 12)  Tominaga M, Ogawa H, Takamori K. Histological characterization of cutaneous nerve fibers containing gastrin-releasing peptide in NC/Nga mice: an atopic dermatitis model. J. Invest. Dermatol., 129, 2901–2905 (2009).
  • 13)  Namer B, Carr R, Johanek LM, Schmelz M, Handwerker HO, Ringkamp M. Separate peripheral pathways for pruritus in man. J. Neurophysiol., 100, 2062–2069 (2008).
  • 14)  Sun YG, Zhao ZQ, Meng XL, Yin J, Liu XY, Chen ZF. Cellular basis of itch sensation. Science, 325, 1531–1534 (2009).
  • 15)  Shim WS, Tak MH, Lee MH, Kim M, Kim M, Koo JY, Lee CH, Kim M, Oh U. TRPV1 mediates histamine-induced itching via the activation of phospholipase A2 and 12-lipoxygenase. J. Neurosci., 27, 2331–2337 (2007).
  • 16)  Xiao B, Patapoutian A. Scratching the surface: a role of pain-sensing TRPA1 in itch. Nat. Neurosci., 14, 540–542 (2011).
  • 17)  Imamachi N, Park GH, Lee H, Anderson DJ, Simon MI, Basbaum AI, Han SK. TRPV1-expressing primary afferents generate behavioral responses to pruritogens via multiple mechanisms. Proc. Natl. Acad. Sci. U.S.A., 106, 11330–11335 (2009).
  • 18)  Wilson SR, Gerhold KA, Bifolck-Fisher A, Liu Q, Patel KN, Dong X, Bautista DM. TRPA1 is required for histamine-independent, Mas-related G protein-coupled receptor-mediated itch. Nat. Neurosci., 14, 595–602 (2011).
  • 19)  Yun JW, Seo JA, Jang WH, Koh HJ, Bae IH, Park YH, Lim KM. Antipruritic effects of TRPV1 antagonist in murine atopic dermatitis and itching models. J. Invest. Dermatol., 131, 1576–1579 (2011).
  • 20)  Lim KM, Park YH. Development of PAC-14028, a novel transient receptor potential vanilloid type 1 (TRPV1) channel antagonist as a new drug for refractory skin diseases. Arch. Pharm. Res., 35, 393–396 (2012).
  • 21)  Sekine R, Satoh T, Takaoka A, Saeki K, Yokozeki H. Anti pruritic effects of topical crotamiton, capsaicin, and a corticosteroid on pruritogen-induced scratching behavior. Exp. Dermatol., 21, 201–204 (2012).
  • 22)  Aioi A, Tonogaito H, Suto H, Hamada K, Ra CR, Ogawa H, Maibach H, Matsuda H. Impairment of skin barrier function in NC/Nga Tnd mice as a possible model for atopic dermatitis. Br. J. Dermatol., 144, 12–18 (2001).
  • 23)  Tanaka A, Jung K, Matsuda A, Jang H, Kajiwara N, Amagai Y, Oida K, Ahn G, Ohmori K, Kang KG, Matsuda H. Daily intake of Jeju groundwater improves the skin condition of the model mouse for human atopic dermatitis. J. Dermatol., 40, 193–200 (2013).
  • 24)  Ishii I, Kurozumi K, Orito K, Matsuda H. Automatic scratching pattern detection for laboratory mice using high-speed video images. IEEE Trans. Autom. Sci. Eng., 5, 176–182 (2008).
  • 25)  Nie Y, Ishii I, Yamamoto K, Orito K, Matsuda H. Real-time scratching behavior quantification system for laboratory mice using high-speed vision. J. Real-Time Image Proc., 2007, 628–633.
 
© 2013 The Pharmaceutical Society of Japan
feedback
Top